Kiromic Biopharma Inc (KRBP) - Total Liabilities
Based on the latest financial reports, Kiromic Biopharma Inc (KRBP) has total liabilities worth $21.13 Million USD as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Kiromic Biopharma Inc (KRBP) cash conversion ratio to assess how effectively this company generates cash.
Kiromic Biopharma Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Kiromic Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. See Kiromic Biopharma Inc (KRBP) net assets for net asset value and shareholders' equity analysis.
Kiromic Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Kiromic Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HPI AG
MU:CEW3
|
Germany | €38.52 Million |
|
Investor Centre Ltd
AU:ICU
|
Australia | AU$3.25 Million |
|
UMT United Mobility Technology AG
XETRA:UMDK
|
Germany | €4.28 Million |
|
Gangotri Textiles Limited
NSE:GANGOTRI
|
India | Rs2.52 Billion |
|
GROUPIMO S.A. INH. EO 1-
F:9KL0
|
Germany | €1.37 Million |
|
Global Li-Ion Graphite Corp
F:0TD
|
Germany | €932.32K |
|
Manolete Partners PLC
LSE:MANO
|
UK | GBX30.89 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Kiromic Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Kiromic Biopharma Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kiromic Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kiromic Biopharma Inc (2018–2024)
The table below shows the annual total liabilities of Kiromic Biopharma Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $21.13 Million | -0.74% |
| 2023-12-31 | $21.29 Million | +20.00% |
| 2022-12-31 | $17.74 Million | +420.33% |
| 2021-12-31 | $3.41 Million | +132.34% |
| 2020-12-31 | $1.47 Million | +117.84% |
| 2019-12-31 | $673.70K | +10.32% |
| 2018-12-31 | $610.70K | -- |
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more